COVID-19 Clinical Trial Resumptions Slow as Cases Rise Again

Published on: October 7, 2020

Clinical trials disrupted by COVID-19 are expected to resume at a much slower rate than originally anticipated, as more nations are re-enforcing lockdown due to a globally rising number of COVID-19 cases, says GlobalData.

Priya Nair, Trials Intelligence Analyst at GlobalData, commented, “The general trend shows a gradual increase in the overall percentage of trials for each trial status*, the biggest of which has been seen in trials that are ongoing and recruiting and those that are ongoing but not recruiting. Between August 17^th and September 21^st, ongoing and recruiting trials decreased from 84.7% to 82.2%, while completed trials increased from 4.5% to 6.4%.”

There is also an overall steady increase of trials resuming activity. The U.S. has the highest number of resumed trials at 70.6%, followed by France at 7.6%, the UK and Spain at 7%.

* Completed; Ongoing, not recruiting; Ongoing, recruiting; Planned

For more of their findings, click here.